The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohema...
Guardado en:
Autor principal: | Kamil D. Kaplanov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/51e15491eb424cc3a2503cf65691ad49 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Leigh Naylor-Adamson, et al.
Publicado: (2021) -
Mantle cell lymphoma
por: V. I. Vorob’ev, et al.
Publicado: (2020) -
Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo J, et al.
Publicado: (2016) -
Mantle cell lymphoma presenting with lethal atraumatic splenic rupture
por: Frederick Eyerer, et al.
Publicado: (2021) -
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Joanne E. Davis, et al.
Publicado: (2021)